Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2002
03/14/2002WO2002020595A1 A novel polypeptide-homo zinc finger protein 18.04 and polynucleotide encoding said polypeptide
03/14/2002WO2002020594A1 A novel polypeptide-homodna topoisomerase ii-beta(top2b)29.48 and polynucleotide encoding said polypeptide
03/14/2002WO2002020593A1 A novel polypeptide - homo nucleoprotein matrix antigen 115.29 and polynucleotide encoding said polypeptide
03/14/2002WO2002020592A1 A novel polypeptide - homo mitochondria translating initiation factor 8.8 and polynucleotide encoding said polypeptide
03/14/2002WO2002020591A1 A novel polypeptide-homo complement receptor 12 and polynucleotide encoding said polypeptide
03/14/2002WO2002020590A1 A novel polypeptide-phosphoenolpyruvate-dependent sugar phosphotransferase 33 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020589A1 A novel polypeptide-the human retinoblastoma binding protein 19.91 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020588A1 A novel polypeptide-human transcriptional control factor zfm1 isomer 25.63 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020587A1 A novel polypeptide-human nadh dehydrogenase subunit i-12.43 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020586A1 A novel polypeptide-human large protein 10.23 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020585A1 A novel polypeptide-homo cytokine signal inhibitory factor socs-5-29 and polynucleotide encoding said polypeptide
03/14/2002WO2002020584A1 A novel polypeptide-homo dna repair protein 10.23 and polynucleotide encoding said polypeptide
03/14/2002WO2002020583A1 A novel polypeptide-homo transcription factorlcr-f19.02 and polynucleotide encoding said polypeptide
03/14/2002WO2002020582A1 A novel polypeptide - homo neurofibroma amplified protein 9.24 and polynucleotide encoding said polypeptide
03/14/2002WO2002020581A1 A novel polypeptide-rna polymerase 11 related protein 11.33 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020580A1 A novel polypeptide-human tnfr/ngfr protein 15 that contains cytochrome c structural domain and the polynucleotide encoding said polypeptide
03/14/2002WO2002020579A1 A novel polypeptide-homo acid phosphatase family protein 11 and polynucleotide encoding said polypeptide
03/14/2002WO2002020578A1 A novel polypeptide-homo mitochondria aspartate aminotransferase 37.29 and polynucleotide encoding said polypeptide
03/14/2002WO2002020577A1 A novel polypeptide-homo ribonucleotide reductase 10.49 and polynucleotide encoding said polypeptide
03/14/2002WO2002020576A1 A novel polypeptide - homo glandulae mammaria susceptibility gene encoding protein 12.32 and polynucleotide encoding said polypeptide
03/14/2002WO2002020575A1 A novel polypeptide-homo autoimmune disease-associated protein 10 and polynucleotide encoding said polypeptide
03/14/2002WO2002020570A2 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening
03/14/2002WO2002020569A2 Mammalian genes; related reagents and methods
03/14/2002WO2002020567A2 Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein
03/14/2002WO2002020565A2 Collections of repeat proteins comprising repeat modules
03/14/2002WO2002020563A2 RECEPTOR IN THE EDb FIBRONECTIN DOMAIN
03/14/2002WO2002020561A1 Novel polypeptides and anti-hiv drugs containing the same
03/14/2002WO2002020560A1 Novel human cancer/testis antigen and gene thereof
03/14/2002WO2002020558A2 Method for binding, in solution, a peptide and a lipophilic vector and uses thereof
03/14/2002WO2002020557A1 Extended native chemical ligation
03/14/2002WO2002020551A1 Antisense modulation of e2f transcription factor 2 expression
03/14/2002WO2002020550A1 Antisense modulation of mekk3 expression
03/14/2002WO2002020549A1 Antisense modulation of glioma-associated oncogene-1 expression
03/14/2002WO2002020547A1 Antisense modulation of bh3 interacting domain death agonist expression
03/14/2002WO2002020546A1 Antisense modulation of phosphorylase kinase alpha 1 expression
03/14/2002WO2002020545A1 Antisense modulation of a20 expression
03/14/2002WO2002020544A1 Process for preparing peptide derivatized oligomeric compounds
03/14/2002WO2002020475A2 Inhibitors of serine protease activity of matriptase or mtsp1
03/14/2002WO2002020466A1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
03/14/2002WO2002020465A2 Gamma-ketoacid dipeptides as inhibitors of caspase-3
03/14/2002WO2002020464A2 Benzene tricarboxylic acid amides as insulin receptor activators
03/14/2002WO2002020092A1 Use of serum response factor (srf) modulator for treating srf related diseases
03/14/2002WO2002020091A2 Antithrombotic compositions
03/14/2002WO2002020060A1 Vp22 protein/nucleic acid aggregates, uses thereof
03/14/2002WO2002020057A2 Flavoring systems for pharmaceutical compositions and methods of making such compositions
03/14/2002WO2002020053A1 Hla binding peptides and their uses
03/14/2002WO2002020047A2 Chlamydial peptides and their mimics in demyelinating disease
03/14/2002WO2002020043A1 Inhibition of adenovirus replication by product r, a peptide nucleic acid immunomodulator
03/14/2002WO2002020040A1 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
03/14/2002WO2002020037A1 Biologically active oral preparation that can be site-specific released in colon
03/14/2002WO2002020036A1 Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or a dna sequence of the koc promoter
03/14/2002WO2002020035A1 Hla binding peptides and their uses
03/14/2002WO2002020034A1 'pseudo'-native chemical ligation
03/14/2002WO2002020033A1 Polymer-modified synthetic proteins
03/14/2002WO2002020032A1 Stat3 agonists and antagonists and therapeutic uses thereof
03/14/2002WO2002020031A2 Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses
03/14/2002WO2002019999A2 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
03/14/2002WO2002019986A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
03/14/2002WO2002019981A2 Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use
03/14/2002WO2002019966A2 Cardiac arrhythmia treatment methods
03/14/2002WO2002019965A2 Heat shock response and virus replication
03/14/2002WO2002019963A2 Synthetic erythropoiesis stimulating proteins
03/14/2002WO2002019962A2 Therapeutic and cosmetic uses of heparanases
03/14/2002WO2002019837A1 Improved bioactive whey protein hydrolysate
03/14/2002WO2001096564A3 Hla-g (hla-g7) isoform and its applications
03/14/2002WO2001094539A3 A human kaza1 inhibitory factor 11 and polynucleotide encoding it
03/14/2002WO2001094534A3 A novel polypeptide, a human transcription factor 9.57 and the polynucleotide encoding the polypeptide
03/14/2002WO2001094531A3 A novel polypeptide, a human uterine globulin 12 and the polynucleotide encoding the polypeptide
03/14/2002WO2001093890A3 Botulinum toxin implant
03/14/2002WO2001093827A3 Neurotoxin implant
03/14/2002WO2001090189A3 G-protein coupled receptor org3.
03/14/2002WO2001085981A3 Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
03/14/2002WO2001085760A8 Thrombin inhibitors
03/14/2002WO2001081535A3 A novel polypeptide, a human pax protein 9.9 and the polynucleotide encoding the polypeptide
03/14/2002WO2001079506A3 Treatment of ocular neovascularization and related diseases
03/14/2002WO2001079505A3 INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
03/14/2002WO2001079278A8 Lactobacillus johnsonii bacteriocin, active against helicobacter pylori
03/14/2002WO2001079268A3 A glycopeptide and preparation thereof
03/14/2002WO2001078696A3 Formulations for use in inhaler devices
03/14/2002WO2001078695A3 Pharmaceutical formulations for dry powder inhalers
03/14/2002WO2001078694A3 Formulations for use in inhaler devices
03/14/2002WO2001077358A3 Herpes viruses for immune modulation
03/14/2002WO2001077320A3 Regulation of human hm74-like g protein coupled receptor
03/14/2002WO2001076644A3 Lipid-based systems for targeting diagnostic agents
03/14/2002WO2001076555A3 Lipid-based drug delivery systems for topical application
03/14/2002WO2001075059A3 A novel polypeptide, human gtp-regulatory protein 11 and a polynucleotide encoding the same
03/14/2002WO2001075048A3 A novel polypeptide, human ribosomal protein s11 23 and the polynucleotide encoding the polypeptide
03/14/2002WO2001072290A3 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
03/14/2002WO2001070986A3 Helical protein zalpha51
03/14/2002WO2001070805A3 Soluble mast cell function associated antigen (mafa) pharmaceutical compositions and methods of making and using them
03/14/2002WO2001070768A3 Receptor-binding compounds and method for identifying them
03/14/2002WO2001070173A3 Immunokine composition and method
03/14/2002WO2001068836A3 Methods and compositions for rna interference
03/14/2002WO2001068124A3 Suppression of vascular disorders by mucosal administration of heat shock protein peptides
03/14/2002WO2001066749A3 A member of the lectin superfamily
03/14/2002WO2001066149A3 Nucleic acid formulations for gene delivery and methods of use
03/14/2002WO2001064920A3 Hybrid expression of neisserial proteins
03/14/2002WO2001064046A3 Method for isolating sponge collagen and producing nanoparticulate collagen, and the use thereof
03/14/2002WO2001062774A3 Purified lh
03/14/2002WO2001061007A3 Fibroblast growth factor-23 molecules and uses thereof
1 ... 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 ... 3163